MediGene AG (MDGEF.PK) Announces Market Launch Of Veregen®: In Belgium, Denmark And Finland
6/12/2014 7:55:02 AM
Martinsried/Munich, 12 June 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces market launches of Veregen® in further three European markets. Medigene's marketing partner Will-Pharma has launched the drug for the treatment of genital warts in Belgium and the marketing partner Azanta A/S will start the launch of Veregen® in Denmark and Finland within the next few weeks.
Veregen® is already available in the USA, in 12 European countries (Germany, Austria, Switzerland, Spain, the Netherlands, Norway, Sweden, the Czech Republic, Poland, Serbia, Hungary, Slovakia) and Taiwan. Market approvals for Veregen® have been granted in a number of other countries. Further market launches and approvals of Veregen® are expected in 2014. Several marketing agreements have been concluded in Europe, Asia, and America.
About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.
About Will-Pharma: Will-Pharma markets and promotes its own ethical products, food supplements and medical devices through its well trained sales force. With its head offices in the three countries of Benelux, Will-Pharma has more than 90 years of experience in the development and sale of drugs, medical devices, and food supplements. Moreover, Will-Pharma has a long standing distribution agreement with Daiichi-Sankyo. More information on Will-Pharma: www.willpharma.com.
About Azanta: Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women's and men's health, and addiction medicine. The vision of Azanta A/S is to become an international market leader for specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets nine specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low-risk development projects for commercialization in the near term. For further information, please visit www.azanta.com.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.com .
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Help employers find you! Check out all the jobs and post your resume.
comments powered by